Alterity Therapeutics (ATHE) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 29, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Aug 29, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ATHE SEC filings page.
Alterity Therapeutics Limited (ATHE) reported $5.3M in revenue for fiscal year 2025, up 85.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Alterity Therapeutics Limited's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Alterity Therapeutics Limited's revenue surged 85.7% year-over-year to $5.3M, reflecting rapid business expansion. This strong growth earns a score of 93/100.
With a current ratio of 12.98, Alterity Therapeutics Limited holds $12.98 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 99/100.
Alterity Therapeutics Limited passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.
Alterity Therapeutics Limited reported a net loss of $8.0M while operations used $7.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Alterity Therapeutics Limited generated $5.3M in revenue in fiscal year 2025. This represents an increase of 85.7% from the prior year.
Alterity Therapeutics Limited reported a net loss of $8.0M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Alterity Therapeutics Limited earned -$0.12 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Alterity Therapeutics Limited held $21.8M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for fiscal year 2025.
Capital Allocation
Alterity Therapeutics Limited invested $9.5M in research and development in fiscal year 2025. This represents a decrease of 23.9% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
ATHE Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.3M+85.7% | $2.9M+9.3% | $2.6M-26.0% | $3.5M+4.8% | $3.4M+3403.9% | $96K-97.3% | $3.5M+2282.5% | $149K+46.5% | $102K-4.1% | $106K |
| R&D Expenses | $9.5M-23.9% | $12.4M+41.6% | $8.8M-13.6% | $10.2M+10.6% | $9.2M+32.3% | $7.0M-23.5% | $9.1M+83.6% | $5.0M+13.3% | $4.4M-38.6% | $7.1M |
| Interest Expense | $4K-15.6% | $5K+58.4% | $3K+92.8% | $2K+62.0% | $974-63.6% | $3K | N/A | N/A | N/A | N/A |
| Income Tax | $45K+45.4% | $31K-55.8% | $70K+44.0% | $48K | N/A | N/A | $0n/m | $0n/m | $0n/m | $0 |
| Net Income | -$8.0Mn/m | -$12.8M | N/A | $8.9M-22.7% | $11.5M+23.7% | $9.3M+7.3% | $8.6Mn/m | -$6.1Mn/m | -$5.8Mn/m | -$5.7M |
| EPS (Basic) | -$0.12 | -$0.35 | -$0.38n/m | -$0.37n/m | -$0.67n/m | -$1.03 | N/A | N/A | N/A | N/A |
| EPS (Diluted) | -$0.12 | -$0.35 | -$0.38n/m | -$0.37n/m | -$0.67n/m | -$1.03n/m | -$1.40 | N/A | N/A | N/A |
| Diluted Shares (Avg) | 6.40B | 3.65B | 2.43B+0.9% | 2.41B+41.8% | 1.70B+89.6% | 895M | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, SG&A Expenses, Operating Income, EBITDA.
ATHE Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $30.3M+135.7% | $12.8M-29.5% | $18.2M-36.3% | $28.6M+13.4% | $25.2M+268.6% | $6.8M-51.1% | $14.0M+0.7% | $13.9M-28.6% | $19.4M | N/A |
| Current Assets | $30.2M+137.2% | $12.7M-29.5% | $18.0M-36.6% | $28.4M+13.2% | $25.1M+270.2% | $6.8M-51.3% | $13.9M+0.9% | $13.8M-28.8% | $19.4M | N/A |
| Cash & Equivalents | $21.8M+158.3% | $8.4M-19.7% | $10.5M-56.3% | $24.0M+14.0% | $21.1M+232.4% | $6.3M-37.2% | $10.1M-10.5% | $11.3M-32.9% | $16.8M-20.9% | $21.3M |
| Accounts Receivable | $2.6M-4.1% | $2.7M-53.3% | $5.8M+77.0% | $3.3M+1.8% | $3.2M+7486.1% | $42K-98.8% | $3.4M+45.1% | $2.3M+0.1% | $2.3M | N/A |
| Total Liabilities | $178.7M+14.7% | $155.8M+5.1% | $148.2M+3541.9% | $4.1M+74.3% | $2.3M+22.9% | $1.9M-19.2% | $2.4M+20.2% | $2.0M+60.2% | $1.2M | N/A |
| Current Liabilities | $2.3M-35.2% | $3.6M+22.9% | $2.9M-27.4% | $4.0M+74.8% | $2.3M+22.9% | $1.9M-19.6% | $2.3M+19.0% | $2.0M+60.2% | $1.2M | N/A |
| Non-Current Liabilities | $58K+67.9% | $35K-57.6% | $82K+60.9% | $51K+42.2% | $36K+22.3% | $29K+19.2% | $25K+3517.1% | $678+100.7% | $338 | N/A |
| Total Equity | -$148.5Mn/m | -$143.0Mn/m | -$130.0M-630.9% | $24.5M+7.2% | $22.8M+363.4% | $4.9M-57.5% | $11.6M-2.5% | $11.9M-34.6% | $18.2M-22.0% | $23.3M |
| Retained Earnings | -$148.5Mn/m | -$143.0Mn/m | -$130.0Mn/m | -$125.6M-198.7% | $127.2Mn/m | -$106.4Mn/m | -$99.0Mn/m | -$95.9Mn/m | -$94.1M-201.4% | $92.8M |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Goodwill, Long-Term Debt.
ATHE Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.5Mn/m | -$8.4Mn/m | -$13.3Mn/m | -$8.5Mn/m | -$13.0Mn/m | -$6.5Mn/m | -$9.8Mn/m | -$4.6Mn/m | -$4.5Mn/m | -$5.5M |
| Capital Expenditures | N/A | $4K-21.6% | $5K-92.1% | $62K+684.2% | $8K-32.0% | $12K+134.5% | $5K-89.3% | $46K+115.5% | $21K+1149.9% | $2K |
| Free Cash Flow | N/A | -$8.4Mn/m | -$13.4Mn/m | -$8.6Mn/m | -$13.0Mn/m | -$6.5Mn/m | -$9.8Mn/m | -$4.7Mn/m | -$4.5Mn/m | -$5.5M |
| Investing Cash Flow | -$4.9Mn/m | -$4Kn/m | -$24Kn/m | -$62Kn/m | -$8Kn/m | -$12Kn/m | -$5Kn/m | -$14Kn/m | -$21Kn/m | -$619 |
| Financing Cash Flow | $26.1M+323.7% | $6.2M+7327.7% | $83K-99.3% | $11.3M-59.1% | $27.5M+901.9% | $2.7M-69.2% | $8.9Mn/m | -$80Kn/m | -$122K | N/A |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Dividends Paid, Share Buybacks.
ATHE Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | -150.2% | -446.0% | N/A | 250.6% | 339.8% | 9622.6% | 243.8% | -4108.8% | -5696.6% | -5418.3% |
| Return on Equity | N/A | N/A | N/A | 36.2%-14.0pp | 50.2%-137.9pp | 188.2%+113.7pp | 74.5%+125.9pp | -51.4%-19.6pp | -31.8%-7.2pp | -24.6% |
| Return on Assets | -26.4%+73.1pp | -99.5% | N/A | 31.1%-14.5pp | 45.6%-90.2pp | 135.8%+73.9pp | 62.0%+106.1pp | -44.1%-14.3pp | -29.8% | N/A |
| Current Ratio | 12.98+9.4x | 3.54-2.6x | 6.17-0.9x | 7.07-3.8x | 10.92+7.3x | 3.62-2.4x | 5.98-1.1x | 7.06-8.8x | 15.88 | N/A |
| Liabilities-to-Equity | N/A | N/A | N/A | 0.17+0.1x | 0.10-0.3x | 0.39+0.2x | 0.200.0x | 0.16+0.1x | 0.07 | N/A |
| Asset Turnover | 0.180.0x | 0.22+0.1x | 0.140.0x | 0.120.0x | 0.13+0.1x | 0.01-0.2x | 0.25+0.2x | 0.010.0x | 0.01 | N/A |
| FCF Margin | N/A | -294.1% | -509.6% | -242.4% | -384.8% | -6755.9% | -275.9% | -3135.4% | -4451.0% | -5201.9% |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$148.5M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Alterity Therapeutics Limited ATHE | FY2025 | $5.3M | -$8.0M | N/A | $40.7M | 48/100 |
| Ovid Therapeutics Inc. OVID | FY2025 | $7.3M | -$17.4M | N/A | $500.0M | 66/100 |
| OS Therapies Incorporated OSTX | FY2025 | N/A | -$28.8M | N/A | $60.8M | — |
| Unicycive Therapeutics, Inc. UNCY | FY2025 | N/A | -$26.6M | N/A | $106.1M | — |
| Cel-Sci Corporation CVM | FY2025 | N/A | -$25.4M | N/A | $26.4M | — |
| Adicet Bio, Inc. ACET | FY2025 | N/A | -$116.8M | N/A | $33.5M | — |
Where Alterity Therapeutics Limited Ranks
Frequently Asked Questions
What is Alterity Therapeutics Limited's annual revenue?
Alterity Therapeutics Limited (ATHE) reported $5.3M in total revenue for fiscal year 2025. This represents a 85.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Alterity Therapeutics Limited's revenue growing?
Alterity Therapeutics Limited (ATHE) revenue grew by 85.7% year-over-year, from $2.9M to $5.3M in fiscal year 2025.
Is Alterity Therapeutics Limited profitable?
No, Alterity Therapeutics Limited (ATHE) reported a net loss of $8.0M in fiscal year 2025.
What is Alterity Therapeutics Limited's operating cash flow?
Alterity Therapeutics Limited (ATHE) recorded an outflow of $7.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Alterity Therapeutics Limited's total assets?
Alterity Therapeutics Limited (ATHE) had $30.3M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Alterity Therapeutics Limited spend on research and development?
Alterity Therapeutics Limited (ATHE) invested $9.5M in research and development during fiscal year 2025.
What is Alterity Therapeutics Limited's current ratio?
Alterity Therapeutics Limited (ATHE) had a current ratio of 12.98 as of fiscal year 2025, which is generally considered healthy.
What is Alterity Therapeutics Limited's return on assets (ROA)?
Alterity Therapeutics Limited (ATHE) had a return on assets of -26.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Alterity Therapeutics Limited's P/E ratio?
Alterity Therapeutics Limited (ATHE) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $40.7M as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Alterity Therapeutics Limited's price-to-sales ratio?
Alterity Therapeutics Limited (ATHE) trades at 7.7x sales, its market capitalization divided by $5.3M revenue, FY2025. The market capitalization is $40.7M as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Why is Alterity Therapeutics Limited's debt-to-equity ratio negative or not reported?
Alterity Therapeutics Limited (ATHE) has negative shareholder equity of -$148.5M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Alterity Therapeutics Limited's Piotroski F-Score?
Alterity Therapeutics Limited (ATHE) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Alterity Therapeutics Limited's earnings high quality?
Alterity Therapeutics Limited (ATHE) reported a net loss of $8.0M while operations used $7.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Alterity Therapeutics Limited?
Alterity Therapeutics Limited (ATHE) scores 48 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.